Anavex Names Interim CEO Kellmeyer, Signals Q1 Filing Delay
AVXL•Anavex Life Sciences named Terrie Kellmeyer, PhD, as interim CEO after board-requested resignation of Christopher Missling and signaled a Form 12b-25 filing to delay its March quarter 10-Q submission. Management emphasized its robust cash position, lack of long-term debt, and continued focus on oral blarcamesine for early Alzheimer’s disease.
1. Interim CEO Appointment
In response to the board’s request for Christopher Missling’s resignation on April 30, 2026, Anavex appointed Terrie Kellmeyer, PhD, former Senior Vice President of Clinical Development, as interim CEO to guide its clinical and regulatory strategy. Kellmeyer brings nearly three decades of pharmaceutical experience in clinical development, regulatory affairs, safety, medical affairs and quality assurance to advance oral blarcamesine trials and other CNS-focused programs.
2. Q1 2026 Filing Delay
The company plans to file a Form 12b-25 to extend the deadline for its quarterly Form 10-Q for the period ended March 31, 2026, creating near-term reporting uncertainty. Management cited the executive transition as a factor in the filing delay and plans to provide further details in an upcoming conference call and webcast.
3. Financial Health and Pipeline Outlook
Anavex reiterated its strong cash position and absence of long-term debt, which it believes will support ongoing neurological disease programs. Under interim CEO Kellmeyer, the company will continue prioritizing oral blarcamesine development for early Alzheimer’s disease alongside its broader CNS pipeline.
